Literature DB >> 16255834

Survival of a national cohort of hepatitis C virus infected patients, 16 years after exposure.

H E Harris1, M E Ramsay, N J Andrews.   

Abstract

The aim of this study was to describe the natural history of HCV after 16 years of infection, in a cohort of individuals who acquired their infections on a known date in the United Kingdom. A total of 924 HCV-infected transfusion recipients (cases) and 475 anti-HCV negative transfusion recipients (controls) were eligible for inclusion in the study. Survival was compared between cases and controls to see if there was any excess mortality attributable to HCV. The results show that all-cause mortality was not significantly different between cases and controls (hazard ratio 1.17, 95% CI 0.92-1.49, P=0.21). However, the risk of death directly from liver disease was higher in cases than controls (hazard ratio 2.71, 95% CI 1.09-6.75, P=0.03). Nearly 30% of those HCV-infected cases who died directly from liver disease were known to have consumed excess alcohol.

Entities:  

Mesh:

Year:  2005        PMID: 16255834      PMCID: PMC2870424          DOI: 10.1017/S0950268805005340

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  12 in total

1.  Hepatitis C--global prevalence (update).

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  1999-12-10

Review 2.  The natural history of hepatitis C-A quandary.

Authors:  L B Seeff
Journal:  Hepatology       Date:  1998-12       Impact factor: 17.425

3.  Long-term persistence of hepatitis C virus antibodies in a single source outbreak.

Authors:  S Dittmann; M Roggendorf; J Dürkop; M Wiese; B Lorbeer; F Deinhardt
Journal:  J Hepatol       Date:  1991-11       Impact factor: 25.083

4.  45-year follow-up of hepatitis C virus infection in healthy young adults.

Authors:  L B Seeff; R N Miller; C S Rabkin; Z Buskell-Bales; K D Straley-Eason; B L Smoak; L D Johnson; S R Lee; E L Kaplan
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

5.  Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group.

Authors:  E Kenny-Walsh
Journal:  N Engl J Med       Date:  1999-04-22       Impact factor: 91.245

6.  The HCV National Register: towards informing the natural history of hepatitis C infection in the UK.

Authors:  H E Harris; M E Ramsay; J Heptonstall; K Soldan; K P Eldridge
Journal:  J Viral Hepat       Date:  2000-11       Impact factor: 3.728

7.  Clinical course of hepatitis C virus during the first decade of infection: cohort study.

Authors:  Helen E Harris; Mary E Ramsay; Nick Andrews; Keith P Eldridge
Journal:  BMJ       Date:  2002-02-23

8.  Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study.

Authors:  L B Seeff; F B Hollinger; H J Alter; E C Wright; C M Cain; Z J Buskell; K G Ishak; F L Iber; D Toro; A Samanta; R L Koretz; R P Perrillo; Z D Goodman; R G Knodell; G Gitnick; T R Morgan; E R Schiff; S Lasky; C Stevens; R Z Vlahcevic; E Weinshel; T Tanwandee; H J Lin; L Barbosa
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

9.  Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group.

Authors:  L B Seeff; Z Buskell-Bales; E C Wright; S J Durako; H J Alter; F L Iber; F B Hollinger; G Gitnick; R G Knodell; R P Perrillo
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

10.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.

Authors:  Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Tony Dans; Alvaro Avezum; Fernando Lanas; Matthew McQueen; Andrzej Budaj; Prem Pais; John Varigos; Liu Lisheng
Journal:  Lancet       Date:  2004 Sep 11-17       Impact factor: 79.321

View more
  6 in total

1.  Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors.

Authors:  Anne M Guiltinan; Zhanna Kaidarova; Brian Custer; Jennie Orland; Angela Strollo; Sherri Cyrus; Michael P Busch; Edward L Murphy
Journal:  Am J Epidemiol       Date:  2008-01-17       Impact factor: 4.897

Review 2.  Chronic hepatitis C and liver fibrosis.

Authors:  Giada Sebastiani; Konstantinos Gkouvatsos; Kostas Pantopoulos
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 3.  The history of the "natural history" of hepatitis C (1968-2009).

Authors:  Leonard B Seeff
Journal:  Liver Int       Date:  2009-01       Impact factor: 5.828

4.  Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C.

Authors:  Phil McEwan; Thomas Ward; Hayley Bennett; Anupama Kalsekar; Samantha Webster; Michael Brenner; Yong Yuan
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

Review 5.  New insights into HCV-related rheumatologic disorders: A review.

Authors:  Patrice Cacoub; Cloé Comarmond
Journal:  J Adv Res       Date:  2016-07-25       Impact factor: 10.479

Review 6.  Hepatitis C virus: A critical approach to who really needs treatment.

Authors:  Elias Kouroumalis; Argyro Voumvouraki
Journal:  World J Hepatol       Date:  2022-01-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.